Enhancing anti-tumour efficacy with immunotherapy combinations

被引：293

作者：

Meric-Bernstam, Funda ^{[1
]}

Larkin, James ^{[2
]}

Tabernero, Josep ^{[3
]}

Bonini, Chiara ^{[4
,5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[2] Royal Marsden NHS FoundationTrust, Canc Serv, London, England

[3] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain

[4] Univ Vita Salute San Raffaele, Expt Hematol Unit, Milan, Italy

[5] Ist Sci San Raffaele, Expt Hematol Unit, IRCCS Osped, Milan, Italy

来源：

LANCET | 2021年 / 397卷 / 10278期

关键词：

NIVOLUMAB PLUS IPILIMUMAB; T-CELLS; PHASE-I; TUMOR MICROENVIRONMENT; DONOR LYMPHOCYTES; ADOPTIVE TRANSFER; DOUBLE-BLIND; PATIENTS PTS; CHEMOTHERAPY; MONOTHERAPY;

D O I：

10.1016/S0140-6736(20)32598-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several tumour types are responsive to immunotherapy, as shown by regulatory approvals for immune checkpoint inhibitors. However, many patients either do not respond or do not have durable clinical benefit. Thus, there is great interest in developing predictors of response to immunotherapy and rational combination therapies that can enhance efficacy by overcoming primary and acquired resistance. In this Review, we provide an assessment of immunotherapy response biomarkers that can identify patients who will benefit from monotherapy rather than from combinations. We review the rationale for combination therapy and different strategies, including combinations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptors and other novel T-cell receptor-based therapies. There are many combination partners in development; therefore, a programmatic approach is needed to develop a framework for biomarker-driven combination therapy selection.

引用

页码：1010 / 1022

页数：13

共 112 条

[1] Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study [J].

Amin, Asim ;

Plimack, Elizabeth R. ;

Ernstoff, Marc S. ;

Lewis, Lionel D. ;

Bauer, Todd M. ;

McDermott, David F. ;

Carducci, Michael ;

Kollmannsberger, Christian ;

Rini, Brian I. ;

Heng, Daniel Y. C. ;

Knox, Jennifer ;

Voss, Martin H. ;

Spratlin, Jennifer ;

Berghorn, Elmer ;

Yang, Lingfeng ;

Hammers, Hans J. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[2] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma [J].

Ascierto, Paolo Antonio ;

Ferrucci, Pier Francesco ;

Fisher, Rosalie ;

Del Vecchio, Michele ;

Atkinson, Victoria ;

Schmidt, Henrik ;

Schachter, Jacob ;

Queirolo, Paola ;

Long, Georgina V. ;

Di Giacomo, Anna Maria ;

Svane, Inge Marie ;

Lotem, Michal ;

Bar-Sela, Gil ;

Couture, Felix ;

Mookerjee, Bijoyesh ;

Ghori, Razi ;

Ibrahim, Nageatte ;

Moreno, Blanca Homet ;

Ribas, Antoni .

NATURE MEDICINE, 2019, 25 (06) :941-+

[3]

Baas P, 2020, J THORAC ONCOL, V15, pE42

[4] A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors [J].

Bentebibel, Salah-Eddine ;

Hurwitz, Michael E. ;

Bernatchez, Chantale ;

Haymaker, Cara ;

Hudgens, Courtney W. ;

Kluger, Harriet M. ;

Tetzlaff, Michael T. ;

Tagliaferri, Mary A. ;

Zalevsky, Jonathan ;

Hoch, Ute ;

Fanton, Christie ;

Aung, Sandra ;

Hwu, Patrick ;

Curti, Brendan D. ;

Tannir, Nizar M. ;

Sznol, Mario ;

Diab, Adi .

CANCER DISCOVERY, 2019, 9 (06) :711-721

[5] PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells [J].

Bernabei, Luca ;

Garfall, Alfred L. ;

Melenhorst, J. Joseph ;

Lacey, Simon F. ;

Stadtmauer, Edward A. ;

Vogl, Dan T. ;

Gonzalez, Vanessa ;

Plesa, Gabriela ;

Young, Regina M. ;

Waxman, Adam ;

Levine, Bruce L. ;

June, Carl H. ;

Milone, Michael C. ;

Cohen, Adam D. .

BLOOD, 2018, 132

[6] Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Itzhaki, Orit ;

Treves, Avraham J. ;

Zippel, Douglas B. ;

Levy, Daphna ;

Kubi, Adva ;

Shoshani, Noa ;

Zikich, Dragoslav ;

Ohayon, Yaara ;

Ohayon, Daniel ;

Shalmon, Bruria ;

Markel, Gal ;

Yerushalmi, Ronit ;

Apter, Sara ;

Ben-Nun, Alon ;

Ben-Ami, Eytan ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4792-4800

[7] The "cancer immunogram" [J].

Blank, Christian U. ;

Haanen, John B. ;

Ribas, Antoni ;

Schumacher, Ton N. .

SCIENCE, 2016, 352 (6286) :658-660

[8] HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].

Bonini, C ;

Ferrari, G ;

Verzeletti, S ;

Servida, P ;

Zappone, E ;

Ruggieri, L ;

Ponzoni, M ;

Rossini, S ;

Mavilio, F ;

Traversari, C ;

Bordignon, C .

SCIENCE, 1997, 276 (5319) :1719-1724

[9] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [J].

Brentjens, Renier J. ;

Davila, Marco L. ;

Riviere, Isabelle ;

Park, Jae ;

Wang, Xiuyan ;

Cowell, Lindsay G. ;

Bartido, Shirley ;

Stefanski, Jolanta ;

Taylor, Clare ;

Olszewska, Malgorzata ;

Borquez-Ojeda, Oriana ;

Qu, Jinrong ;

Wasielewska, Teresa ;

He, Qing ;

Bernal, Yvette ;

Rijo, Ivelise V. ;

Hedvat, Cyrus ;

Kobos, Rachel ;

Curran, Kevin ;

Steinherz, Peter ;

Jurcic, Joseph ;

Rosenblat, Todd ;

Maslak, Peter ;

Frattini, Mark ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)

[10] CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma [J].

Casucci, Monica ;

di Robilant, Benedetta Nicolis ;

Falcone, Laura ;

Camisa, Barbara ;

Norelli, Margherita ;

Genovese, Pietro ;

Gentner, Bernhard ;

Gullotta, Fabiana ;

Ponzoni, Maurilio ;

Bernardi, Massimo ;

Marcatti, Magda ;

Saudemont, Aurore ;

Bordignon, Claudio ;

Savoldo, Barbara ;

Ciceri, Fabio ;

Naldini, Luigi ;

Dotti, Gianpietro ;

Bonini, Chiara ;

Bondanza, Attilio .

BLOOD, 2013, 122 (20) :3461-3472

← 1 2 3 4 5 6 7 8 9 10 →